Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus

INTRODUCTION: Canagliflozin is a sodium glucose co-transporter 2 inhibitor approved worldwide for the treatment of patients with type 2 diabetes mellitus (T2DM). The present study evaluated pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with T2DM. METHODS: Canag...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Adv Ther
Hlavní autoři: Iijima, Hiroaki, Kifuji, Takayuki, Maruyama, Nobuko, Inagaki, Nobuya
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Healthcare 2015
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4569680/
https://ncbi.nlm.nih.gov/pubmed/26280756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-015-0234-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky